2021 Webinar - An overview of Effiris 2.1; An enhanced qualitative model suite for anticipating and mitigating adverse drug reactions – Slides and recording
Effiris delivers state-of-the-art secondary pharmacology models, where each model has had the opportunity to learn from the private data of all pharmaceutical collaborators. As a result, Effiris overcomes one of the main challenges facing model development in drug discovery - leveraging the breadth of available high-quality proprietary data.
Adrian and Phil presented how Effiris can be used to enhance secondary pharmacology profiling through the use of federated QSAR models - which have been appropriately trained from multi-party data, including proprietary and public sources. The webinar also included a demonstration of the new features being delivered in this enhanced version of Effiris.